Evidence map›Paper›PMID 34586572›Full record

ArticleJournal of thrombosis and thrombolysis2022

The safety and efficacy of systemic versus catheter-based therapies: application of a prognostic model by a pulmonary embolism response team.

Jean-Pierre Iskandar, Essa Hariri, Christopher Kanaan, Nicholas Kassis, Hayaan Kamran, Denise Sese, Colin Wright, Mark Marinescu, Scott J Cameron

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jean-Pierre Iskandar *Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Essa Hariri *Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Christopher KanaanDepartment of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Nicholas KassisDepartment of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Hayaan KamranDepartment of Cardiovascular Medicine, Section of Vascular Medicine, Heart Vascular and Thoracic Institute, Desk J-35, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA.
Denise SeseDepartment of Pulmonary Critical Care, Cleveland Clinic Foundation, Cleveland, OH, USA.
Colin WrightUniversity of Rochester Medical Center, Rochester, NY, USA.
Mark MarinescuUniversity of Rochester Medical Center, Rochester, NY, USA.
Scott J CameronDepartment of Cardiovascular Medicine, Section of Vascular Medicine, Heart Vascular and Thoracic Institute, Desk J-35, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA. cameros3@ccf.org.ORCID http://orcid.org/0000-0002-9616-1540
Cleveland Clinic · USUniversity of Rochester Medical Center · US

Funding

Platelets as Biosensors and Mediators of Aortic Aneurysm GrowthR01HL158801 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI CAMERON, SCOTT JAMES · 2021 to 2025
$2.5M
Platelet ERK5 regulates myocardial infarct expansionK08HL128856 · NHLBI · UNIVERSITY OF ROCHESTER · PI CAMERON, SCOTT JAMES · 2016 to 2020
$775k
NHLBI NIH HHS HL120200NHLBI NIH HHS K08 HL128856NHLBI NIH HHS K08HL128856NHLBI NIH HHS L30 HL120200NHLBI NIH HHS R01 HL158801
6 · The paper itself

Abstract

The decision by pulmonary embolism response teams (PERTs) to utilize anticoagulation (AC) with or without systemic thrombolysis (ST) or catheter-directed therapies (CDT) for pulmonary embolism (PE) is a balance between the desire for a positive outcome and safety. Our primary aim was to develop a predictive model of in-hospital mortality for patients with high- or intermediate-risk PE managed by PERT while externally validating this model. Our secondary aim was to compare the relative safety and efficacy of ST and CDT in this cohort. Consecutive patients hospitalized between June 2014 and January 2020 at the Cleveland Clinic Foundation and The University of Rochester with acute high- or intermediate-risk PE managed by PERT were retrospectively evaluated. Groups were stratified by treatment strategy. The primary outcome was in-hospital mortality, and secondary outcome was major bleeding. A logistic regression model to predict the primary outcome was built using the derivation cohort, with 100-fold bootstrapping for internal validation. External validation was performed and the area under the receiver operating curve (AUC) was calculated. Of 549 included patients, 421 received AC alone, 71 received ST, and 64 received CDT. Predictors of major bleeding include ESC risk category, PESI score, hypoxia, hemodynamic instability, and serum lactate. CDT trended towards lower mortality but with an increased risk of bleeding relative to ST (OR = 0.42; 95% CI [0.15, 1.17] and OR = 2.14; 95% CI [0.9, 5.06] respectively). In the multivariable logistic regression model in the derivation institution cohort, predictors of in-hospital mortality were age, cancer, hemodynamic instability requiring vasopressors, and elevated NT-proBNP (AUC = 0.86). This model was validated using the validation institution cohort (AUC = 0.88). We report an externally-validated model for predicting in-hospital mortality in patients with PE managed by PERT. The decision by PERT to initiate CDT or ST for these patients had no impact on mortality or major bleeding, yet the long-term efficacy of these interventions needs to be elucidated.

Indexed as

Pulmonary EmbolismThrombolytic TherapyCathetersFibrinolytic AgentsHemorrhageHumansPrognosisRetrospective StudiesTreatment OutcomeFibrinolytic AgentsCatheter-directed thrombolysisMortalityPulmonary embolismPulmonary embolism response teamThrombolysis

Identifiers

PMID34586572
OpenAlexW3202131693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.